Safety and feasibility of CDK4/6 inhibitors treatment combined with radiotherapy in patients with HR-positive/HER2-negative breast cancer. A systematic review and meta-analysis

医学 内科学 中止 放射治疗 不利影响 肿瘤科 乳腺癌 毒性 荟萃分析 癌症 转移性乳腺癌 胃肠病学
作者
Marcin Kubeczko,Michał Jarząb,Dorota Gabryś,Aleksandra Krzywon,Alexander Jorge Cortez,Amy J. Xu
出处
期刊:Radiotherapy and Oncology [Elsevier BV]
卷期号:187: 109839-109839 被引量:1
标识
DOI:10.1016/j.radonc.2023.109839
摘要

Background and PurposeThe addition of cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) to endocrine therapy in hormone receptor-positive (HR+) human epidermal growth factor 2-negative (HER2-) breast cancer has led to practice-changing improvements in overall survival. However, there are conflicting data concerning the safety of CDK4/6i combination with radiotherapy, and no consensus guidelines exist to guide practice. We conducted a meta-analysis to assess the safety and feasibility of CDK4/6i treatment with radiotherapy.Materials and MethodsA comprehensive search was performed in PubMed/MEDLINE, Web of Science, and Scopus, for studies in advanced/metastatic breast cancer receiving CDK4/6i and radiotherapy with the provided safety data on the occurrence of toxicity. The main outcomes were safety (grade 3-5 adverse events), CDK 4/6i dose reduction, and the discontinuation rate due to toxicity.ResultsFifteen studies comprising 1133 patients with HR+/HER2- breast cancer patients were included. Among them, 617 pts received CDK4/6i and radiotherapy; the median follow-up was 17.0 months (IQR 9.2 – 18.0), and the median age was 58.8 years (IQR 55.5 - 62.5). The pooled prevalence of severe hematologic toxicity was 29.4% (95% CI 14.0% – 47.4%; I2 = 93%; τ2 = 0.084; p < 0.01 and severe non-hematologic toxicity was 2.8% (95% CI 1.1% – 4.8%; I2 = 0%; τ2 = 0.0; p = 0.67). The pooled prevalence of CDK4/6i dose reduction was 24.0% (95% CI 11.1% – 39.4%; I2 = 90%; τ2 = 0.052; p < 0.01) with no difference between CDK4/6i plus RT vs. CDK4/6i (odds ratio of 0.934; 95% CI 0.66 – 1.33; I2 = 0%; τ2 = 0.0; p = 0.56). The pooled prevalence of CDK4/6i discontinuation due to toxicity was 2.3% (95% CI 0.4% – 5.2%; I2 = 23%; τ2 = 0.002; p = 0.24).ConclusionThe findings of this study suggest that radiotherapy in addition to CDK4/6i treatment in breast cancer patients is generally safe and well tolerated and remains a viable treatment option.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
体贴的叛逆者完成签到,获得积分10
1秒前
幸福的鑫鹏完成签到,获得积分10
1秒前
孤海未蓝完成签到,获得积分10
2秒前
彭于晏应助飒飒采纳,获得10
3秒前
狠毒的小龙虾完成签到,获得积分10
4秒前
小趴菜完成签到,获得积分10
8秒前
lcls完成签到,获得积分10
9秒前
9秒前
10秒前
尊敬太阳发布了新的文献求助10
12秒前
风中夜天完成签到 ,获得积分10
12秒前
优雅友蕊完成签到,获得积分10
13秒前
gaga完成签到,获得积分10
14秒前
西北孤傲的狼完成签到,获得积分10
15秒前
多边形完成签到 ,获得积分10
17秒前
李cc完成签到,获得积分10
19秒前
19秒前
快帮我找找完成签到,获得积分10
19秒前
xiezhuochun完成签到 ,获得积分10
20秒前
23秒前
aixiaoming0503完成签到,获得积分10
24秒前
forge完成签到,获得积分10
24秒前
25秒前
Distance完成签到,获得积分10
28秒前
蒋念寒发布了新的文献求助10
29秒前
雪雨夜心完成签到,获得积分10
33秒前
又是一年完成签到,获得积分10
34秒前
Distance发布了新的文献求助10
35秒前
李子完成签到 ,获得积分10
36秒前
36秒前
耍酷的指甲油完成签到,获得积分20
37秒前
安小磊完成签到 ,获得积分10
38秒前
雄i完成签到,获得积分10
41秒前
明亮的遥完成签到 ,获得积分0
43秒前
安澜完成签到,获得积分10
43秒前
MG_XSJ应助1111采纳,获得10
46秒前
尊敬太阳完成签到,获得积分20
47秒前
48秒前
量子星尘发布了新的文献求助30
49秒前
健壮安柏完成签到 ,获得积分10
50秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038184
求助须知:如何正确求助?哪些是违规求助? 3575908
关于积分的说明 11373872
捐赠科研通 3305715
什么是DOI,文献DOI怎么找? 1819255
邀请新用户注册赠送积分活动 892662
科研通“疑难数据库(出版商)”最低求助积分说明 815022